Screening for hepatitis C at the emergency department: Should babyboomers also be screened in Belgium?


Journal

Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857

Informations de publication

Date de publication:
04 2019
Historique:
received: 16 07 2018
revised: 27 11 2018
accepted: 27 11 2018
pubmed: 14 12 2018
medline: 19 5 2020
entrez: 8 12 2018
Statut: ppublish

Résumé

Patients are not screened adequately for hepatitis C virus infection in Belgium. In the USA, the Center for Disease Control recommends screening for patients born in the babyboom period (1945-1965). In Europe, the babyboom cohort was born between 1955 and 1974, but no screening policy has been targeted to this group. We aimed to study the prevalence of hepatitis C virus in an emergency department population in Belgium and the risk factors associated with hepatitis C virus infection. We performed a monocentric, cross-sectional seroprevalence study between January and November 2017 in a large Belgian non-university hospital. Patients aged 18-70 years presenting at the emergency department were eligible. Patients completed a risk assessment questionnaire and were screened for hepatitis C virus antibodies (Ab) with reflex hepatitis C virus ribonucleic acid testing. Of 2970 patients, 2366 (79.7%) agreed to participate. hepatitis C virus Ab prevalence was 1.31%. Twenty-one (67.7%) hepatitis C virus Ab-positive patients were born between 1955 and 1974. With a previous treatment uptake of 54.5%, the prevalence of viremia was 0.9% in retrospect; 0.2% were newly diagnosed. The weighted multiple logistic regression model identified males born in the 1955-1974 cohort, intravenous drug use and high endemic birth country as significant risk factors for hepatitis C virus infection (P < 0.05). Although the prevalence of hepatitis C virus Ab at the emergency department was higher than previously estimated for the general population in Belgium, the number of newly diagnosed patients with viremia was low. To optimize screening strategies, screening should be offered to males born in the 1955-1974 cohort, but especially in drug users, the prison population and immigrants from high endemic countries.

Sections du résumé

BACKGROUND & AIMS
Patients are not screened adequately for hepatitis C virus infection in Belgium. In the USA, the Center for Disease Control recommends screening for patients born in the babyboom period (1945-1965). In Europe, the babyboom cohort was born between 1955 and 1974, but no screening policy has been targeted to this group. We aimed to study the prevalence of hepatitis C virus in an emergency department population in Belgium and the risk factors associated with hepatitis C virus infection.
METHOD
We performed a monocentric, cross-sectional seroprevalence study between January and November 2017 in a large Belgian non-university hospital. Patients aged 18-70 years presenting at the emergency department were eligible. Patients completed a risk assessment questionnaire and were screened for hepatitis C virus antibodies (Ab) with reflex hepatitis C virus ribonucleic acid testing.
RESULTS
Of 2970 patients, 2366 (79.7%) agreed to participate. hepatitis C virus Ab prevalence was 1.31%. Twenty-one (67.7%) hepatitis C virus Ab-positive patients were born between 1955 and 1974. With a previous treatment uptake of 54.5%, the prevalence of viremia was 0.9% in retrospect; 0.2% were newly diagnosed. The weighted multiple logistic regression model identified males born in the 1955-1974 cohort, intravenous drug use and high endemic birth country as significant risk factors for hepatitis C virus infection (P < 0.05).
CONCLUSION
Although the prevalence of hepatitis C virus Ab at the emergency department was higher than previously estimated for the general population in Belgium, the number of newly diagnosed patients with viremia was low. To optimize screening strategies, screening should be offered to males born in the 1955-1974 cohort, but especially in drug users, the prison population and immigrants from high endemic countries.

Identifiants

pubmed: 30525269
doi: 10.1111/liv.14016
doi:

Substances chimiques

Hepatitis C Antibodies 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

667-675

Informations de copyright

© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Auteurs

Rob Bielen (R)

Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.
Department of Gastroenterology, Ziekenhuis-Oost Limburg, Genk, Belgium.

Cécile Kremer (C)

Faculty of Science, Center for statistics, Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Diepenbeek, Belgium.

Özgür M Koc (ÖM)

Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.
Department of Gastroenterology, Ziekenhuis-Oost Limburg, Genk, Belgium.
Medical Microbiology, School of NUTRIM, Maastricht University Medical Centre, Maastricht, The Netherlands.

Dana Busschots (D)

Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.
Department of Gastroenterology, Ziekenhuis-Oost Limburg, Genk, Belgium.

Diana M Hendrickx (DM)

Faculty of Science, Center for statistics, Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Diepenbeek, Belgium.

Pascal Vanelderen (P)

Department of Anaesthesiology, Intensive Care Medicine, Emergency Care and Pain Therapy, Ziekenhuis-Oost Limburg, Genk, Belgium.

Niel Hens (N)

Faculty of Science, Center for statistics, Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Diepenbeek, Belgium.
Centre for Health Economic Research and Modelling of Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute(VAXINFECTIO), University of Antwerp, Antwerp, Belgium.

Frederik Nevens (F)

Department of Gastroenterology and Hepatology, University Hospitals KULeuven, Leuven, Belgium.

Geert Robaeys (G)

Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.
Department of Gastroenterology, Ziekenhuis-Oost Limburg, Genk, Belgium.
Department of Gastroenterology and Hepatology, University Hospitals KULeuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH